|01/17/17||Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome|
|Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects
Company to Host Conference Call and Webcast Today at 4:30pm ET/ 1:30pm PT
SAN DIEGO, Jan. 17, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the top-line results from the Company's Phase II T-Forward study of INGREZZA™ (valbenazine), a highly-selective small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in adults with Tourette syndrome. While the study showed ... |
|01/06/17||Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer|
|SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that David-Alexandre "DA" Gros M.D. has joined the executive management team as President and Chief Operating Officer.
"Neurocrine is very pleased to welcome Dr. Gros as our President and Chief Operating Officer as we move forward with our transformation into a commercial entity," said Kevin Gorman, Chief Executive Of... |
|01/05/17||Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia|
|Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT
SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA), after further review of the INGREZZA™ (valbenazine) New Drug Application (NDA), has decided to cancel the Psychopharmacologic Drugs Advisory Committee meeting which was originally scheduled for February 16, 2017. The FDA informed the Company that the Priority... |
|01/03/17||Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference|
|Live Audio Webcast will be on January 9, 2017
SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco.
The live presentation takes place on Monday, January 9 at 2:30pm PT (5:30pm ET). The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.